minocycline and Vertigo

The aim of this study was to evaluate the therapeutic benefit of minocycline in mucous membrane pemphigoid (MMP) predominantly involving the oral cavity. A descriptive, open clinical study with no control group, including 9 patients, was developed. The diagnosis was confirmed by histopathological examination and direct and salt-split-skin indirect immunofluorescence analysis. Target antigens were sought by immunoblotting. Patients received minocycline (200mg/day) for a variable period. All patients were followed up for at least 2 years after initial diagnosis. Therapeutic response was assessed by clinical improvement in three categories: major response, minor response and no response. A major response was observed in 3 patients (33%), a minor response in 4 (44%) and 2 (22%) patients showed no improvement. Two of the 3 patients with a major response showed no immunoblot reactivity; 80% of patients with circulating autoantibodies (autoAb) against BP180 had a minor or no response. Permanent remission of signs with no relapse was only obtained in one patient. 5 patients (55%) stopped the drug because of adverse effects, such as vertigo and gastralgia. The results revealed temporary clinical benefits in MMP predominantly involving the oral cavity with minocycline, although frequently side effects led to drug withdrawal.

Topics: Administration, Oral; Administration, Topical; Aged; Anti-Bacterial Agents; Clobetasol; Complement C3; Drug Combinations; Female; Fluorescent Antibody Technique, Indirect; Gingival Diseases; Glucocorticoids; Humans; Immunoglobulin A; Immunoglobulin G; Middle Aged; Minocycline; Pemphigoid, Benign Mucous Membrane; Treatment Outcome; Vertigo

Two randomized studies to test the efficacy of a combination of Piracetam and Ergotoxin on the destabilized brainstem are reported. In the first study, a pharmacological model using Minocycline is employed. A follow-up clinical study analysed the effect of the preparation in 5 patients suffering from vertigo and other related complaints. It was seen that there was a significant improvement in the nystagmus profiles of the pharmacological model volunteers. Similarly, the patient group showed a marked improvement in symptoms, and in orientation capability as tested by Cranio-Corpo-Graphy.

Topics: Adult; Brain Stem; Double-Blind Method; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Female; Follow-Up Studies; Humans; Minocycline; Piracetam; Pyrrolidinones; Random Allocation; Tetracyclines; Vertigo

By means of a former investigation it has been proved equilibriometrically that the application of 7 X 100 mg minocycline may induce a central equilibrium dysregulation of the brainstem type. It was the purpose of this study to further assure that the minocycline induced brainstem vertigo is due to a destabilization of a supervisory gamma-aminobutyric acid (GABA)ergic loop from the archeocerebellum upon the pontomedullary vestibular regulating pathways. As it is pharmacologically known that pyridoxine is essential for the synthesis of GABA, an inhibitory CNS neurotransmitter, 2 separate double blind trials on 20 healthy young persons each were carried out after the intake of 7 X 100 mg minocycline during 3 days with and without 7 X 40 mg pyridoxine simultaneously. These trials were checked against an additional placebo or initial non drug investigation. In all the 40 test persons it could be proved that the amount of vertigo and nausea symptoms was increased significantly due to the application of minocycline only. However, when combining minocycline with vitamin B 6, the vertigo and nausea symptoms as well as the nystagmus signs from the monaural and the binaural vestibular ocular tests as well as the vestibular spinal signs from the craniocorpography recordings of the stepping and the standing procedures were remarkably reduced. There were no statistical differences between the initial or placebo trials versus the trials with a combination of minocycline with vitamin B 6. The same holds for the vestibular vegetative reactions, measured by the simultaneous electrocardiography during the vestibular tests. All the equilibriometric tests applied showed a significant destabilization under the influence of a pure minocycline loading.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Adult; Double-Blind Method; Electronystagmography; Female; Heart Rate; Humans; Male; Minocycline; Pyridoxine; Tetracyclines; Vertigo

A high rate of side effects (mostly vestibular) was found among 83 people receiving prophylaxis with minocycline because of contact with a patient who had died of meningitis due to Neisseria meningitidis. Three groups of contacts received different lots of minocycline and different dosage regimens. Seventy-eight percent of these people had symptoms temporally related to ingestion of minocycline. These symptoms, which included dizziness, nausea, vomiting, vertigo, anorexia, and headache, generally commenced soon after initiation of chemoprophylaxis; the total dosage of minocycline was low. The high rate of vestibular side effects of minocycline militates against widespread use of minocycline for prophylaxis of meningococcal infection.

Topics: Adult; Anorexia; Clinical Trials as Topic; Female; Headache; Humans; Meningitis, Meningococcal; Minocycline; Nausea; Neisseria meningitidis; Tetracyclines; Vertigo; Vestibule, Labyrinth; Vomiting

Topics: Clinical Trials as Topic; Drug Tolerance; Humans; Minocycline; Tetracycline; Vertigo; Vestibule, Labyrinth

Cogan's syndrome is a rare clinical entity defined by the association of a nonsyphilitic interstitial keratitis and vestibuloauditory dysfunction, typically Menière's disease-like; the condition has been reported in association with a variety of cutaneous diseases. We now report a case of pyoderma gangrenosum complicating Cogan's syndrome in a 57-year-old woman, which then healed dramatically, as more interestingly did the associated uveitis with minocycline therapy.

Topics: Ataxia; Deafness; Female; Humans; Keratitis; Meniere Disease; Middle Aged; Minocycline; Nausea; Pyoderma Gangrenosum; Syndrome; Uveitis; Vertigo; Vomiting

Topics: Adolescent; Adult; Child; Erythrocytes; Family; Female; Humans; Ion Channels; Male; Middle Aged; Minocycline; Phenotype; Potassium; Tetracyclines; Vertigo; Vestibule, Labyrinth

Minocycline hydrochloride is a tetracycline derivative that has been advocated as the drug of choice in the treatment of meningococcal carriers. Recently, we studied a group of 30 patients who experienced a large number of side-effects after receiving minocycline for treatment of meningococcal meningitis. Twenty-seven of 30 (90%) suffered from dizziness, vertigo, ataxia, weakness, nausea, and vomiting. These symptoms appeared within the first 72 hours of taking minocycline, and disappeared within 48 hours of stopping the medication.

Topics: Adult; Ataxia; Child; Female; Humans; Male; Meningitis, Meningococcal; Minocycline; Nausea; Tetracyclines; Vertigo; Vomiting

Topics: Asthma; Bronchitis; Drug Tolerance; Female; Humans; Minocycline; Tetracycline; Vertigo; Vestibule, Labyrinth